{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:06:08Z","timestamp":1791277568327,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"DOI":"10.1007\/s11926-026-01218-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:12:33Z","timestamp":1774343553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beh\u00e7et's Syndrome"],"prefix":"10.1007","volume":"28","author":[{"given":"Yusuf","family":"Yazici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"1218_CR1","first-page":"820","volume":"15","author":"S Yurdakul","year":"1988","unstructured":"Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet\u2019s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15:820\u20132.","journal-title":"J Rheumatol"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet\u2019s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Med (Baltim). 2003;82:60\u201376.","journal-title":"Med (Baltim)"},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/ard.55.3.208","volume":"55","author":"S Yurdakul","year":"1996","unstructured":"Yurdakul S, Tuzuner N, Yurdakul I, et al. Gastrointestinal involvement in Behcet\u2019s syndrome: a controlled study. Ann Rheum Dis. 1996;55:208\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"1218_CR4","first-page":"S502","volume":"56","author":"Y Yazici","year":"2007","unstructured":"Yazici Y, Adler NM. Clinical manifestations and ethnic background of patients with Behcet\u2019s syndrome in a US cohort. Arthritis Rheum. 2007;56(suppl):S502.","journal-title":"Arthritis Rheum"},{"key":"1218_CR5","first-page":"386","volume":"19","author":"SA Munoz","year":"2023","unstructured":"Munoz SA, Kostianovsky A, Allievi A, et al. Beh\u00e7et disease in Latin American countries: a systematic literature review of demographic and clinical features, and HLA-B*51 allele frequency. Rheumatol Clin. 2023;19:386\u201391.","journal-title":"Rheumatol Clin"},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1093\/rheumatology\/keaf224","volume":"64","author":"JLL Lorentsen","year":"2025","unstructured":"Lorentsen JLL, Brunborg C, Aasebo AT, et al. Incidence and prevalence of Behcet\u2019s disease in Oslo, Norway: a two-decade population. -based Anal Rheumatol. 2025;64:4703\u201312.","journal-title":"-based Anal Rheumatol"},{"key":"1218_CR7","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease. Criteria for diagnosis of Beh\u00e7et\u2019s Disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet"},{"key":"1218_CR8","first-page":"338","volume":"28","author":"F Davatchi","year":"2013","unstructured":"Davatchi F, Assaad-Khalil S, Calamia KT, et al. The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013;28:338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12891-017-1463-y","volume":"18","author":"T Blake","year":"2017","unstructured":"Blake T, Pickup L, Carruthers D, et al. Birmingham Beh\u00e7et\u2019s service: classification of disease and application of the 2014 International Criteria for Beh\u00e7et\u2019s Disease (ICBD) to a UK cohort. BMC Musculoskelet Disord. 2017;18:101.","journal-title":"BMC Musculoskelet Disord"},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/s10165-012-0696-8","volume":"23","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi T, Kishimoto M, Swearingen CJ, et al. Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Beh\u00e7et\u2019s syndrome for patients in the US and Japan: data from a large, three-center cohort study. Mod Rheumatol. 2013;23:547\u201353.","journal-title":"Mod Rheumatol"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/art.24642","volume":"61","author":"M de Menthon","year":"2009","unstructured":"de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51\/B5 and the risk of Beh\u00e7et\u2019s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287\u201396.","journal-title":"Arthritis Rheum"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ng.2520","volume":"45","author":"Y Kirino","year":"2013","unstructured":"Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et\u2019s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45:202\u20137.","journal-title":"Nat Genet"},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard-2022-222277","volume":"81","author":"A Cavers","year":"2022","unstructured":"Cavers A, Kugler MC, Ozguler Y, et al. Beh\u00e7et\u2019s disease risk-variant HLA-B51\/ERAP1-Hap10 alters human CD8 T cell immunity. Ann Rheum Dis. 2022;81:1603\u201311.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0000000000000003","volume":"26","author":"A Gul","year":"2014","unstructured":"Gul A. Genetics of Beh\u00e7et\u2019s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26:56\u201363.","journal-title":"Curr Opin Rheumatol"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.berh.2011.05.002","volume":"25","author":"G Hatemi","year":"2011","unstructured":"Hatemi G, Yazici H. Beh\u00e7et\u2019s syndrome and micro-organisms. Best Pract Res Clin Rheumatol. 2011;25:389\u2013406.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1186\/s40168-018-0520-6","volume":"6","author":"Z Ye","year":"2018","unstructured":"Ye Z, Zhang N, Wu C, et al. A metagenomic study of the gut microbiome in Behcet\u2019s disease. Microbiome. 2018;6:1357\u201323.","journal-title":"Microbiome"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3389\/fimmu.2020.01192","volume":"11","author":"TB n der Houwen","year":"2020","unstructured":"n der Houwen TB, van Laar JAM, Kappen JH, et al. Beh\u00e7et\u2019s Disease Under Microbiotic Surveillance? A Combined Analysis of Two Cohorts of Beh\u00e7et\u2019s Disease Patients. Front Immunol. 2020;11:1192.","journal-title":"Front Immunol"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/rheumatology\/ker423","volume":"51","author":"M Karaca","year":"2012","unstructured":"Karaca M, Hatemi G, Sut N, et al. The papulopustular lesion\/arthritis cluster of Beh\u00e7et\u2019s syndrome also clusters in families. Rheumatology (Oxford). 2012;51:1053\u201360.","journal-title":"Rheumatology (Oxford)"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","volume":"128","author":"G Emmi","year":"2021","unstructured":"Emmi G, Bettiol A, Niccolai E, et al. Butyrate-Rich Diets Improve Redox Status and Fibrin Lysis in Beh\u00e7et\u2019s Syndrome. Circ Res. 2021;128:278\u201380.","journal-title":"Circ Res"},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","volume":"10","author":"G Emmi","year":"2019","unstructured":"Emmi G, Becatti M, Bettiol A, et al. Beh\u00e7et\u2019s Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils. Front Immunol. 2019;10:1085.","journal-title":"Front Immunol"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"590622","DOI":"10.3389\/fimmu.2020.590622","volume":"11","author":"L Li","year":"2021","unstructured":"Li L, Yu X, Liu J, et al. Neutrophil Extracellular Traps Promote Aberrant Macrophages Activation in Beh\u00e7et\u2019s Disease. Front Immunol. 2021;11:590622.","journal-title":"Front Immunol"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","volume":"38","author":"EJ Folco","year":"2018","unstructured":"Folco EJ, Mawson TL, Vromman A, et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1\u03b1 and Cathepsin G. Arterioscler Thromb Vasc Biol. 2018;38:1901\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1218_CR23","first-page":"2071","volume":"42","author":"E Bektas","year":"2024","unstructured":"Bektas E, Buyukdemir A, Yalcinkaya Y, et al. ABO blood groups and increased risk for the development of vascular involvement in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2024;42:2071\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","volume":"10","author":"G Emmi","year":"2019","unstructured":"Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C, et al. Beh\u00e7et\u2019s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol. 2019;10:1085.","journal-title":"Front Immunol"},{"key":"1218_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/art.42486","volume":"75","author":"A Le Joncour","year":"2023","unstructured":"Le Joncour A, R\u00e9gnier P, Maciejewski-Duval A, et al. Reduction of neutrophil activation by phosphodiesterase 4 blockade in Beh\u00e7et\u2019s disease. Arthritis Rheumatol. 2023;75:1628\u201337.","journal-title":"Arthritis Rheumatol"},{"key":"1218_CR26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","volume":"78","author":"A Le Joncour","year":"2019","unstructured":"Le Joncour A, Martos R, Loyau S, et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet\u2019s disease. Ann Rheum Dis. 2019;78:1274\u201382.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s10238-023-01173-3","volume":"23","author":"P Ellergezen","year":"2023","unstructured":"Ellergezen P, Coskun BN, Cecen GS, et al. Assessment of \u03b19\u03b21 integrin as a new diagnostic and therapeutic target in Behcet\u2019s disease. Clin Exp Med. 2023;23:5345\u201353.","journal-title":"Clin Exp Med"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41598-025-87130-4","volume":"15","author":"Y Pu","year":"2025","unstructured":"28-Pu Y, Liang J, Wang Y, et al. Integrated analysis of genetic, proteinic, and metabolomic alterations in Beh\u00e7et\u2019s disease. Sci Rep. 2025;15:2746.","journal-title":"Sci Rep"},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2174\/1568010053622894","volume":"4","author":"A G\u00fcl","year":"2005","unstructured":"G\u00fcl A. Beh\u00e7et\u2019s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:813.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"109630","DOI":"10.1016\/j.clim.2023.109630","volume":"251","author":"E Seyahi","year":"2023","unstructured":"Seyahi E, Ugurlu S, Amikishiyev S, Gul A. Beh\u00e7et disease, familial Mediterranean fever and MEFV variations: More than just an association. Clin Immunol. 2023;251:109630.","journal-title":"Clin Immunol"},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/31.11.767","volume":"31","author":"DM Main","year":"1992","unstructured":"Main DM, Chamberlain MA. Clinical differentiation of oral ulceration in Beh\u00e7et\u2019s disease. Br J Rheumatol. 1992;31:767\u201370.","journal-title":"Br J Rheumatol"},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1365-4632.2006.02859.x","volume":"45","author":"MC Mat","year":"2006","unstructured":"Mat MC, Goksugur N, Engin B, Yurdakul S, et al. The frequency of scarring after genital ulcers in Beh\u00e7et\u2019s syndrome: a prospective study. Int J Dermatol. 2006;45:554\u20136.","journal-title":"Int J Dermatol"},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1309\/GCTH-0060-55K8-XCTT","volume":"116","author":"C Demirkesen","year":"2001","unstructured":"Demirkesen C, Tuzuner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Beh\u00e7et syndrome. Am J Clin Pathol. 2001;116:341\u20136.","journal-title":"Am J Clin Pathol"},{"key":"1218_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-014-8425-z","volume":"49","author":"Y Ozyazgan","year":"2015","unstructured":"Ozyazgan Y, Ucar D, Hatemi G, et al. Ocular Involvement of Beh\u00e7et\u2019s Syndrome: A Comprehensive Review. Clin Rev Allergy Immunol. 2015;49:298\u2013306.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1218_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, Kotter I, Wallace GR, et al. Behcet\u2019s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111\u201336.","journal-title":"Prog Retin Eye Res"},{"key":"1218_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/09273948.2013.854393","volume":"22","author":"I Tugal-Tutkun","year":"2014","unstructured":"36-Tugal-Tutkun I, Onal S, Ozyazgan Y, et al. Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Beh\u00e7et uveitis. Ocul Immunol Inflamm. 2014;22:461\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1218_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","volume":"91","author":"E Seyahi","year":"2012","unstructured":"Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients. Med (Baltim). 2012;91:35\u201348.","journal-title":"Med (Baltim)"},{"key":"1218_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00415-009-0145-6","volume":"256","author":"A Siva","year":"2009","unstructured":"Siva A, Saip S. The spectrum of nervous system involvement in Beh\u00e7et\u2019s syndrome and its differential diagnosis. J Neurol. 2009;256:513\u201329.","journal-title":"J Neurol"},{"key":"1218_CR39","doi-asserted-by":"publisher","first-page":"117436","DOI":"10.1016\/j.jns.2021.117436","volume":"426","author":"U Uygunoglu","year":"2021","unstructured":"Uygunoglu U, Siva A. An uncommon disease included commonly in the differential diagnosis of neurological diseases: Neuro-Beh\u00e7et\u2019s syndrome. J Neurol Sci. 2021;426:117436.","journal-title":"J Neurol Sci"},{"key":"1218_CR40","doi-asserted-by":"publisher","first-page":"e3348","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet\u2019s Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. Med (Baltim). 2016;95:e3348.","journal-title":"Med (Baltim)"},{"key":"1218_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/1751-2980.12965","volume":"22","author":"L Gong","year":"2021","unstructured":"Gong L, Zhang YL, Sun LX, et al. Mucosal healing in intestinal Beh\u00e7et\u2019s disease: A systematic review and meta-analysis. J Dig Dis. 2021;22:83\u201390.","journal-title":"J Dig Dis"},{"key":"1218_CR42","doi-asserted-by":"publisher","unstructured":"Durmaz ES, Acar KH, Kara Avci O et al. Coronary artery disease in Beh\u00e7et\u2019s syndrome: a coronary computed tomography angiography study. Rheumatology (Oxford) 2025 Oct 17:keaf551. https:\/\/doi.org\/10.1093\/rheumatology\/keaf551. Epub ahead of print. PMID: 41105213.","DOI":"10.1093\/rheumatology\/keaf551"},{"key":"1218_CR43","doi-asserted-by":"publisher","first-page":"e005382","DOI":"10.1136\/rmdopen-2024-005382","volume":"11","author":"Y Kayadibi","year":"2025","unstructured":"Kayadibi Y, Ozguler Y, Melikoglu M, et al. Venous vessel-wall assessment with superb microvascular imaging in Beh\u00e7et syndrome. RMD Open. 2025;11:e005382.","journal-title":"RMD Open"},{"key":"1218_CR44","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00259-024-06986-2","volume":"52","author":"K Zhong","year":"2025","unstructured":"Zhong K, Chen H, Hou P, et al. Comparison of [18F]FAPI-42 and [18F]FDG PET\/CT in the evaluation of systemic vasculitis. Eur J Nucl Med Mol Imaging. 2025;52:1083\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1218_CR45","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/09273948.2021.1872652","volume":"30","author":"BH Kim","year":"2022","unstructured":"Kim BH, Park UC, Park SW, et al. Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet\u2019s Uveitis. Ocul Immunol Inflamm. 2022;30:1347\u201353.","journal-title":"Ocul Immunol Inflamm"},{"key":"1218_CR46","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1080\/09273948.2025.2491568","volume":"33","author":"MJ Ghanbarnia","year":"2025","unstructured":"Ghanbarnia MJ, Ghochani G, Khalili Pour E, et al. Association of Optical Coherence Tomography Angiography Biomarkers with Fluorescein Angiography Retinal Inflammation Scores in Behcet\u2019s Retinal Vasculitis. Ocul Immunol Inflamm. 2025;33:1534\u201341.","journal-title":"Ocul Immunol Inflamm"},{"key":"1218_CR47","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s00417-023-06249-0","volume":"261","author":"MFK De\u011firmenci","year":"2023","unstructured":"De\u011firmenci MFK, Yal\u00e7\u0131nda\u011f FN. Are optical coherence tomography and fluorescein angiography comparable for detection of macular edema in Beh\u00e7et uveitis? Graefes Arch Clin Exp Ophthalmol. 2023;261:3275\u201381.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1218_CR48","first-page":"1999","volume":"42","author":"G Hatemi","year":"2024","unstructured":"48-Hatemi G, Seyahi E, Fresko I, et al. Beh\u00e7et\u2019s syndrome: one year in review 2024. Clin Exp Rheumatol. 2024;42:1999\u20132007.","journal-title":"Clin Exp Rheumatol"},{"key":"1218_CR49","doi-asserted-by":"publisher","first-page":"106638","DOI":"10.1016\/j.msard.2025.106638","volume":"102","author":"J Oumerzouk","year":"2025","unstructured":"Oumerzouk J, Hafidi J, Abdellaoui M, et al. MRI findings in neuro-Beh\u00e7et\u2019s disease. About 104 moroccan patients and literature review. Mult Scler Relat Disord. 2025;102:106638. https:\/\/doi.org\/10.1016\/j.msard.2025.106638. Epub 2025 Jul 23. PMID: 40737963.","journal-title":"Mult Scler Relat Disord"},{"key":"1218_CR50","first-page":"1211","volume":"10","author":"Y Li","year":"2023","unstructured":"Li Y, Xiong Z, Jiang Y, et al. Enhancing the Differentiation between Intestinal Beh\u00e7et\u2019s Disease and Crohn\u2019s Disease through Quantitative Computed Tomography Analysis. Bioeng (Basel). 2023;10:1211.","journal-title":"Bioeng (Basel)"},{"key":"1218_CR51","doi-asserted-by":"publisher","first-page":"900458","DOI":"10.3389\/fmed.2022.900458","volume":"9","author":"H Yang","year":"2022","unstructured":"Yang H, Zhang H, Liu W, et al. Computed tomography enterography increases the ability of endoscopy to differentiate Crohn\u2019s disease from intestinal Beh\u00e7et\u2019s disease. Front Med (Lausanne). 2022;9:900458.","journal-title":"Front Med (Lausanne)"},{"key":"1218_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5217\/ir.2023.00129","volume":"22","author":"K Yaguchi","year":"2024","unstructured":"Yaguchi K, Kunisaki R, Sato S, et al. Intestinal ultrasound for intestinal Beh\u00e7et disease reflects endoscopic activity and histopathological findings. Intest Res. 2024;22:297\u2013309.","journal-title":"Intest Res"},{"key":"1218_CR53","doi-asserted-by":"publisher","first-page":"EVIDoa2300354","DOI":"10.1056\/EVIDoa2300354","volume":"3","author":"D Saadoun","year":"2024","unstructured":"Saadoun D, Maalouf G, Vieira M, et al. Infliximab versus Cyclophosphamide for Severe Beh\u00e7et\u2019s Syndrome. NEJM Evid. 2024;3:EVIDoa2300354.","journal-title":"NEJM Evid"},{"key":"1218_CR54","doi-asserted-by":"publisher","first-page":"109682","DOI":"10.1016\/j.clim.2023.109682","volume":"253","author":"G Hatemi","year":"2023","unstructured":"Hatemi G, Tukek NB, Esatoglu SN, et al. Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome. Clin Immunol. 2023;253:109682.","journal-title":"Clin Immunol"},{"key":"1218_CR55","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1016\/S2665-9913(24)00194-2","volume":"6","author":"Z Zhong","year":"2024","unstructured":"55-Zhong Z, Deng D, Gao Y, et al. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Beh\u00e7et\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. Lancet Rheumatol. 2024;6:e780\u201390.","journal-title":"Lancet Rheumatol"},{"key":"1218_CR56","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/rheumatology\/keae585","volume":"64","author":"RJ Moots","year":"2025","unstructured":"Moots RJ, Fortune F, Jackson R, et al. Infliximab vs interferon-\u03b1 in the treatment of Beh\u00e7et\u2019s syndrome: clinical data from the BIO-BEH\u00c7ET\u2019S randomized controlled trial. Rheumatology (Oxford). 2025;64:2882\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"1218_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1515\/rir-2025-0010","volume":"6","author":"RJ Moots","year":"2025","unstructured":"Moots RJ, Fortune F, Jackson R, et al. Predicting response to infliximab and interferon-\u03b1 in Beh\u00e7et\u2019s syndrome: An exploratory analysis from the BIO-BEH\u00c7ET\u2019S randomized controlled trial. Rheumatol Immunol Res. 2025;6:70\u20139.","journal-title":"Rheumatol Immunol Res"},{"key":"1218_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/ard-2024-226113","volume":"84","author":"R Talarico","year":"2024","unstructured":"Talarico R, Italiano N, Emmi G, et al. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis. 2024;84:504\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1218_CR59","doi-asserted-by":"publisher","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","volume":"58","author":"N Barroso-Garc\u00eda","year":"2023","unstructured":"Barroso-Garc\u00eda N, Atienza-Mateo B, Ferraz-Amaro I, et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153.","journal-title":"Semin Arthritis Rheum"},{"key":"1218_CR60","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.3390\/jcm13237388","volume":"13","author":"N Barroso-Garc\u00eda","year":"2024","unstructured":"Barroso-Garc\u00eda N, Mart\u00edn-Varillas JL, Ferraz-Amaro I, et al. Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Beh\u00e7et\u2019s Disease. J Clin Med. 2024;13:7388.","journal-title":"J Clin Med"},{"key":"1218_CR61","doi-asserted-by":"publisher","first-page":"1759720X2211240","DOI":"10.1177\/1759720X221124014","volume":"14","author":"J Zou","year":"2022","unstructured":"Zou J, Cai JF, Ye JF, et al. Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et\u2019s syndrome. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124014.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1218_CR62","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu J, Yu X, Wang Z, et al. Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: A pilot study. Clin Immunol. 2023;247:109241.","journal-title":"Clin Immunol"},{"key":"1218_CR63","doi-asserted-by":"publisher","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","volume":"250","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang X, Liu W, et al. Baricitinib for the treatment of refractory vascular Beh\u00e7et\u2019s disease. Clin Immunol. 2023;250:109298.","journal-title":"Clin Immunol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01218-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:03:22Z","timestamp":1774350202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01218-y","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Y Yazici: Consultant: Amgen, Chugai, Soligenix, argenx, Hemay. G Hatemi: Consultant: Bayer, Celgene, Johnson&Johnson. Expert testimony: Deva Pharmaceuticals. Grants: Celgene, Amgen, Lilly. Honoraria: UCB Pharma. Development of educational content: AbbVie, Boehringer Ingelheim, Novartis, UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a review article and does not contain any new studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"10"}}